Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 3
2021 5
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
Yamani A, Zdżalik-Bielecka D, Lipner J, Stańczak A, Piórkowska N, Stańczak PS, Olejkowska P, Hucz-Kalitowska J, Magdycz M, Dzwonek K, Dubiel K, Lamparska-Przybysz M, Popiel D, Pieczykolan J, Wieczorek M. Yamani A, et al. Among authors: dubiel k. Eur J Med Chem. 2021 Jan 15;210:112990. doi: 10.1016/j.ejmech.2020.112990. Epub 2020 Nov 7. Eur J Med Chem. 2021. PMID: 33199155 Review.
Discovery and development of CPL207280 as new GPR40/FFA1 agonist.
Mach M, Bazydło-Guzenda K, Buda P, Matłoka M, Dzida R, Stelmach F, Gałązka K, Wąsińska-Kałwa M, Smuga D, Hołowińska D, Dawid U, Gurba-Bryśkiewicz L, Wiśniewski K, Dubiel K, Pieczykolan J, Wieczorek M. Mach M, et al. Among authors: dubiel k. Eur J Med Chem. 2021 Dec 15;226:113810. doi: 10.1016/j.ejmech.2021.113810. Epub 2021 Sep 1. Eur J Med Chem. 2021. PMID: 34537444
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole Derivatives.
Stypik M, Zagozda M, Michałek S, Dymek B, Zdżalik-Bielecka D, Dziachan M, Orłowska N, Gunerka P, Turowski P, Hucz-Kalitowska J, Stańczak A, Stańczak P, Mulewski K, Smuga D, Stefaniak F, Gurba-Bryśkiewicz L, Leniak A, Ochal Z, Mach M, Dzwonek K, Lamparska-Przybysz M, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: dubiel k. Pharmaceuticals (Basel). 2022 Jul 30;15(8):949. doi: 10.3390/ph15080949. Pharmaceuticals (Basel). 2022. PMID: 36015098 Free PMC article.
Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties.
Staroń J, Kurczab R, Warszycki D, Satała G, Krawczyk M, Bugno R, Lenda T, Popik P, Hogendorf AS, Hogendorf A, Dubiel K, Matłoka M, Moszczyński-Pętkowski R, Pieczykolan J, Wieczorek M, Zajdel P, Bojarski AJ. Staroń J, et al. Among authors: dubiel k. Eur J Med Chem. 2020 Jan 1;185:111857. doi: 10.1016/j.ejmech.2019.111857. Epub 2019 Nov 7. Eur J Med Chem. 2020. PMID: 31734022 Free article.
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.
Stypik M, Michałek S, Orłowska N, Zagozda M, Dziachan M, Banach M, Turowski P, Gunerka P, Zdżalik-Bielecka D, Stańczak A, Kędzierska U, Mulewski K, Smuga D, Maruszak W, Gurba-Bryśkiewicz L, Leniak A, Pietruś W, Ochal Z, Mach M, Zygmunt B, Pieczykolan J, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: dubiel k. Pharmaceuticals (Basel). 2022 Jul 27;15(8):927. doi: 10.3390/ph15080927. Pharmaceuticals (Basel). 2022. PMID: 36015075 Free PMC article.
The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415).
Michałek S, Gurba-Bryśkiewicz L, Maruszak W, Zagozda M, Maj AM, Ochal Z, Dubiel K, Wieczorek M. Michałek S, et al. Among authors: dubiel k. RSC Adv. 2022 Nov 23;12(52):33605-33611. doi: 10.1039/d2ra07003k. eCollection 2022 Nov 22. RSC Adv. 2022. PMID: 36505705 Free PMC article.
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
Dulak-Lis M, Bujak A, Gala K, Banach M, Kędzierska U, Miszkiel J, Hucz-Kalitowska J, Mroczkiewicz M, Stypik B, Szymczak K, Gunerka P, Dubiel K, Zygmunt BM, Wieczorek M, Pieczykolan JS. Dulak-Lis M, et al. Among authors: dubiel k. J Pharmacol Sci. 2021 Apr;145(4):340-348. doi: 10.1016/j.jphs.2021.02.002. Epub 2021 Feb 9. J Pharmacol Sci. 2021. PMID: 33712286 Free article.
Implementation of QbD Approach to the Development of Chromatographic Methods for the Determination of Complete Impurity Profile of Substance on the Preclinical and Clinical Step of Drug Discovery Studies.
Gurba-Bryśkiewicz L, Dawid U, Smuga DA, Maruszak W, Delis M, Szymczak K, Stypik B, Moroz A, Błocka A, Mroczkiewicz M, Dubiel K, Wieczorek M. Gurba-Bryśkiewicz L, et al. Among authors: dubiel k. Int J Mol Sci. 2022 Sep 14;23(18):10720. doi: 10.3390/ijms231810720. Int J Mol Sci. 2022. PMID: 36142622 Free PMC article.
17 results